QIAGEN is a molecular diagnostics and life science tools company that helps clinical and research labs extract, process, and analyze biological samples — a workflow it calls "sample to insight." The business has two broad categories: diagnostics and life science tools. On the diagnostics side, QIAGEN's key products are QIAstat-Dx, a syndromic testing platform that identifies pathogens from a single patient sample, and QuantiFERON-TB Gold, a blood-based latent tuberculosis test that is gradually displacing the older tuberculin skin test globally. On the life science tools side, QIAGEN sells automated sample preparation instruments and kits (QIAsymphony, QIAcube, EZ2) for DNA, RNA, and protein extraction, a digital PCR platform (QIAcuity) used in research and clinical applications, and a bioinformatics software business (QIAGEN Digital Insights) for interpreting next-generation sequencing data. QIAGEN's business model is razor-and-blades: instruments are placed in labs to build an installed base that consumes proprietary reagents, kits, and cartridges over many years, with roughly 90% of revenue recurring. QIAGEN also partners with pharma companies to co-develop companion diagnostic tests, claiming a leading position globally with over 35 major pharma contracts. Customers include hospital labs, public health agencies, pharma and biotech companies, and academic institutions. QIAGEN sells through a direct sales force and distribution partners, and manufactures primarily in Europe.